Thrivent Financial for Lutherans’s Dr. Reddy's Laboratories RDY Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-149,675	Closed	-$2M	–	2533
2023 Q3	$2M	Sell	149,675 -540	-0.4%	-$7.31K	﹤0.01%	1290
2023 Q2	$1.9M	Buy	150,215 +79,370	+112%	+$927K	﹤0.01%	1374
2023 Q1	$807K	Hold	70,845	–	–	﹤0.01%	1908
2022 Q4	$733K	Buy	+70,845	New	+$764K	﹤0.01%	1923
2020 Q4	–	Sell	-25,690	Closed	-$357K	–	2489
2020 Q3	$357K	Sell	25,690 -91,550	-78%	-$1.09M	﹤0.01%	2129
2020 Q2	$1.24M	Sell	117,240 -55,250	-32%	-$562K	﹤0.01%	1354
2020 Q1	$1.39M	Buy	172,490 +29,765	+21%	+$248K	0.01%	1123
2019 Q4	$1.16M	Buy	142,725 +103,105	+260%	+$814K	﹤0.01%	1364
2019 Q3	$300K	Buy	+39,620	New	+$295K	﹤0.01%	2036

Other funds holding RDY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Thrivent Financial for Lutherans's RDY Position: Q4 2023 in Review

Thrivent Financial for Lutherans sold out of Dr. Reddy's Laboratories (RDY) in Q4 2023, closing a stake of 149,675 shares — an estimated $2M sold.

Thrivent Financial for Lutherans first reported a position in RDY in Q3 2019 and held it in 9 quarters. The position peaked at $2M in Q3 2023. 224 funds tracked by Wall St. Rank hold RDY as of Q4 2023.

Thrivent Financial for Lutherans reported no remaining Dr. Reddy's Laboratories position as of Q4 2023 after selling out during the quarter.
Thrivent Financial for Lutherans sold 149,675 Dr. Reddy's Laboratories shares in Q4 2023, an estimated $2M.
Thrivent Financial for Lutherans first reported a position in Dr. Reddy's Laboratories in Q3 2019 and held it in 9 quarters.
Thrivent Financial for Lutherans's Dr. Reddy's Laboratories position peaked at $2M in Q3 2023.
224 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2023, filed 14 Feb 2024.